8-K: Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement

Amarin Corporation plc announces it has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on the Nasdaq Capital Market.

Summary

• Amarin Corporation plc received confirmation from Nasdaq on April 29, 2025, that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1).
• The company's American Depositary Shares (ADSs) had maintained an average closing share price of at least $1.00 over the last 10 consecutive business days ending on April 28, 2025.
• Amarin had previously been notified of non-compliance due to its ADS price falling below $1.00 for 30 consecutive business days.
• To regain compliance, Amarin adjusted the ratio of its ADSs to its ordinary shares from 1:1 to 1:20 on April 11, 2025.
• Amarin is now in full compliance with all Nasdaq listing requirements and will continue to be listed and traded on Nasdaq.
• The company remains focused on maximizing the global value of VASCEPA/VAZKEPA.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has resolved a compliance issue and is focused on its key product. However, forward-looking statements are subject to risks.

Positives

• Amarin has successfully regained compliance with Nasdaq listing requirements.
• The company's continued listing on Nasdaq provides stability and access to capital markets.
• Management is focused on maximizing the value of VASCEPA/VAZKEPA, a key product for the company.

Risks

• The press release contains forward-looking statements that are subject to risks and uncertainties.
• Amarin's filings with the SEC, including the annual report on Form 10-K for the fiscal year ended 2024, contain a list and description of risks associated with an investment in Amarin.

Future Outlook

Amarin will continue its focus on maximizing the value of VASCEPA/VAZKEPA globally for the millions of patients who can benefit from it.

Management Comments

• Aaron Berg, President & CEO, stated that maintaining the public listing on the Nasdaq Capital Market is an important step for the Company.
• Aaron Berg stated that the company will continue its focus on maximizing the value of VASCEPA/VAZKEPA globally.

Industry Context

Maintaining Nasdaq listing is crucial for pharmaceutical companies like Amarin as it ensures access to capital and investor confidence, which are vital for funding research, development, and commercialization of drugs like VASCEPA/VAZKEPA.

Comparison to Industry Standards

• Many pharmaceutical companies face challenges in maintaining Nasdaq compliance, especially during periods of clinical trial setbacks or market volatility.
• Companies like BioCryst Pharmaceuticals and Xeris Biopharma have also faced similar compliance issues related to minimum bid price requirements.
• Amarin's successful regain of compliance positions it favorably compared to companies that have been delisted or have struggled to meet Nasdaq standards.

Stakeholder Impact

• Shareholders: Regaining compliance with Nasdaq listing requirements is positive for shareholder value.
• Employees: Continued listing on Nasdaq provides stability for the company and its employees.
• Patients: Amarin's focus on VASCEPA/VAZKEPA could benefit patients with cardiovascular disease.

Key Dates

Keywords

Nasdaq, compliance, minimum bid price, listing, Amarin, VASCEPA, VAZKEPA, ADS